GMAB: Three key phase III oncology readouts are imminent, targeting major commercial opportunities
Three major phase III readouts are expected next quarter, including pivotal data for epcoritamab in first-line DLBCL, petosemtamab in head and neck cancer, and Rina-S in PROC. Epcoritamab and petosemtamab are positioned for significant commercial opportunities, with Rina-S aiming for best-in-class…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.